From Surf Wiki (app.surf) — the open knowledge base
ZymoGenetics
Former biotechnology company
Former biotechnology company
| Field | Value |
|---|---|
| name | ZymoGenetics |
| logo | ZymoGenetics logo.png |
| image_size | 225px |
| image_caption | Zymogenetics headquarters, as viewed from Lake Union in Seattle, Washington |
| native_name_lang | |
| type | Public |
| industry | Biotechnology/Pharmaceuticals |
| founded | in Seattle, Washington |
| founders | Earl W. Davie, Michael Smith and Benjamin D. Hall |
| hq_location | Lake Union Steam Plant Building |
| hq_location_city | 1201 Eastlake Avenue East, Seattle |
| hq_location_country | Washington, USA |
| area_served | |
| key_people | Stephanie Feldt |
| products | Pharmaceuticals |
| owner | Bristol-Myers Squibb |
| homepage | Archived website |
ZymoGenetics, Inc was one of the oldest biotechnology/pharmaceutical companies in the USA, based in Seattle, Washington. The company was involved in the development of therapeutic proteins. Located on Lake Union, the address of the ZymoGenetics headquarters was 1201 Eastlake Avenue East. It was closed in 2019 after its acquisition by Bristol Myers Squibb.
The company was founded in 1981 by Professors Earl W. Davie and Benjamin D. Hall of the University of Washington and 1993 Nobel Laureate in Chemistry Michael Smith of the University of British Columbia. Initially named Zymos, the company was forced to change its name to ZymoGenetics under threat of trademark infringement from the similarly named semiconductor company ZyMOS. Soon after its founding, ZymoGenetics began working on recombinant proteins with Danish company Novo Nordisk, and was acquired by that company in 1988. It was spun off as a public company in 2000. Bristol-Myers Squibb acquired the company in 2010 for $885 million.
ZymoGenetics' headquarters occupied the landmark Lake Union Steam Plant building beginning in the mid-1990s. This structure was built from 1914 to 1921 by Seattle City Light, the municipal electric utility. At the time, the building was in poor condition with many broken windows; Bruce Carter, the chief executive at the time, described it as "the mother of all fixer-uppers". In December 2016, ZymoGenetics announced that they would not renew the lease to the Steam Plant building, due to expire in 2019; the Fred Hutchinson Cancer Research Center later moved into it. At the time, ZymoGenetics did not plan on closing its Bothell manufacturing site; however, it was sold to Seattle Genetics in August 2017. ZymoGenetics closed completely in 2019.
Corporate governance
In late 2013, the company's president, Stephen W. Zaruby, left and took up the president and chief executive officer roles at Aurinia Pharmaceuticals.
References
References
- "ZymoGenetics, a Bristol-Myers Squibb Company". Bristol-Myers Squibb.
- McGrane, Clare. (November 1, 2018). "Bristol-Myers Squibb will close its Seattle Zymogenetics operations next year". [[GeekWire]].
- Romano, Benjamin. (November 1, 2018). "Seattle biotech stalwart ZymoGenetics prepares for year-end closure". [[The Seattle Times]].
- (25 January 2011). "Bristol-Myers Squibb to Stay in Seattle, Keep ZymoGenetics Workers". [[Xconomy]].
- "In Remembrance: Dr. Benjamin D. Hall (1932-2019)".
- "Dr. Ben Hall - November 1, 2011".
- (13 October 2010). "Novo Nordisk completes divestment of ZymoGenetics, Inc.".
- (23 October 2000). "ZymoGenetics Will Become Independent of Novo Nordisk". [[The New York Times]].
- (8 September 2010). "BMS forges $885M deal to buy ZymoGenetics". FierceBiotech.
- (September 7, 2010). "Bristol-Myers Squibb buying ZymoGenetics".
- (1993-07-04). "Focus: Seattle; Transforming a Rundown Lake Shoreline (Published 1993)".
- Romano, Benjamin. (June 15, 2018). "The Hutch's 30-year journey to the Lake Union steam plant". [[The Seattle Times]].
- Lerman, Rachel. (December 14, 2016). "ZymoGenetics won't renew South Lake Union lease". [[The Seattle Times]].
- Romano, Benjamin. (June 11, 2018). "Hutch cancer center will put labs in Seattle's historic Lake Union steam plant". [[The Seattle Times]].
- Erb, George. (August 1, 2017). "Seattle Genetics buys biotech factory in Bothell". [[The Seattle Times]].
- Slatko, Joshua. (December 2013). "BMS changes senior management team".
This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page.
Ask Mako anything about ZymoGenetics — get instant answers, deeper analysis, and related topics.
Research with MakoFree with your Surf account
Create a free account to save articles, ask Mako questions, and organize your research.
Sign up freeThis content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.
Report